MUNICH, October 19, 2025--(BUSINESS WIRE)--Tubulis today announced positive early clinical data from its NAPISTAR1-01 Phase I/IIa study (NCT06303505) in a late-breaking oral presentation at the ...
The MarketWatch News Department was not involved in the creation of this content. -- TUB-040 demonstrated robust clinical activity with a favorable safety profile and excellent tolerability in ...
"The interim results demonstrated a highly differentiated clinical profile for TUB-040 in the ADC field, with anti-tumor activity beginning at low doses with a broad therapeutic window that could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback